Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors.

Vincenzo FormicaCristina MorelliAnna PatrikidouCarmen MuriasSabeeh ButtAntonella NardecchiaJessica LucchettiNicola RenziKai-Keen ShiuMario RoselliHendrik-Tobias Arkenau

Published in: Targeted oncology (2021)

GIPI, combining NLR, CRP, and albumin, is the first inflammatory index with a significant prognostic value in patients with mOGJ/GC receiving ICIs. GIPI merits validation in independent cohorts and prospective clinical trials.

Keyphrases

clinical trial
oxidative stress

randomized controlled trial
mass spectrometry

high resolution
gas chromatography

double blind